ARDX Company Profile and Key Details
NASDAQ : ARDX
Ardelyx
$7.74
0.74+10.57%
At Close 4:00 PM56.76
BESG ScoreESG Rating
Price Chart
Stock Price Today
Ardelyx, Inc. (ARDX) stock surged +10.57%, trading at $7.74 on NASDAQ, up from the previous close of $7.00. The stock opened at $7.30, fluctuating between $7.22 and $8.05 in the recent session.
Stock Snapshot
7
Prev. Close
1.85B
Market Cap
7.219
Day Low
-33.65
P/E Ratio
-0.23
EPS (TTM)
-0.39
Cash Flow per Share
7.3
Open
239.47M
Number of Shares
8.05
Day High
96.54%
Free Float in %
0.72
Book Value
17.85M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jan 09, 2026 | 7.30 | 8.05 | 7.22 | 7.74 | 17.89M |
| Jan 08, 2026 | 6.17 | 7.10 | 6.12 | 7.00 | 15.43M |
| Jan 07, 2026 | 5.61 | 6.07 | 5.59 | 5.83 | 7.22M |
| Jan 06, 2026 | 6.03 | 6.12 | 5.53 | 5.56 | 5.03M |
| Jan 05, 2026 | 6.16 | 6.24 | 5.65 | 6.09 | 7.99M |
| Jan 02, 2026 | 5.84 | 6.40 | 5.81 | 6.15 | 8.29M |
| Dec 31, 2025 | 5.80 | 5.91 | 5.77 | 5.83 | 3.22M |
| Dec 30, 2025 | 5.82 | 5.99 | 5.72 | 5.80 | 2.9M |
| Dec 29, 2025 | 5.75 | 5.79 | 5.69 | 5.78 | 1.95M |
| Dec 26, 2025 | 5.93 | 5.95 | 5.73 | 5.74 | 2M |
| Dec 24, 2025 | 5.80 | 6.04 | 5.77 | 5.99 | 1.51M |
| Dec 23, 2025 | 5.83 | 5.84 | 5.72 | 5.80 | 1.98M |
| Dec 22, 2025 | 5.78 | 5.90 | 5.71 | 5.84 | 2.43M |
| Dec 19, 2025 | 5.68 | 5.85 | 5.63 | 5.68 | 6.55M |
| Dec 17, 2025 | 5.97 | 6.06 | 5.78 | 5.79 | 2.85M |
| Dec 16, 2025 | 6.19 | 6.23 | 5.98 | 6.00 | 2.46M |
| Dec 15, 2025 | 6.21 | 6.41 | 6.14 | 6.20 | 2.68M |
| Dec 12, 2025 | 6.03 | 6.30 | 5.92 | 6.21 | 3.72M |
| Dec 11, 2025 | 5.91 | 6.04 | 5.83 | 5.90 | 2.41M |
| Dec 10, 2025 | 5.84 | 5.97 | 5.77 | 5.92 | 3.01M |
Contact Details
About Company
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Company Information
| Employees | 395 |
| Beta | 0.55 |
| Sales or Revenue | $124.46M |
| 5Y Sales Change% | 11.237% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
-4.46-0.56%
Regeneron Pharmaceuticals, Inc.$796.55ARGX-7.07997-0.89%
argenx SE$788.49MDGL-42.16-7.58%
Madrigal Pharmaceuticals, Inc.$514.06UTHR-7.6-1.55%
United Therapeutics Corporation$483.23VRTX-5.82-1.24%
Vertex Pharmaceuticals Incorporated$463.86ALNY-1.11-0.28%
Alnylam Pharmaceuticals, Inc.$398.29KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83PRAX-5.93-2.01%
Praxis Precision Medicines, Inc.$288.45KRYS12.5+5.02%
Krystal Biotech, Inc.$261.41SGEN-0.16-0.07%
Seagen Inc.$228.74Technical Performance
ARDX has shown sold momentum, gaining 20.07% over the past week and 35.4% over the past quarter, though year-to-date performance is up 20.07%. Short-term trend indicators are bearishly aligned (SMA20 28.35%, SMA50 32.32%, SMA200 52.03%). The stock’s 14-day RSI is 74.0 (overbought), while the ATR of 0.44 points to higher daily volatility. The stock remains hovering near 52-week lows, trading 9.01% below its high and over 141.12% above its low. Average 10-day trading volume of 9.30 million shares is significantly above the 3-month average of 4.02 million, indicating heightened recent market interest.
Valuation Metrics
Ardelyx, Inc. trades at a P/E ratio of -33.11, slightly below the S&P 500 average, with a price-to-sales ratio of 4.65 and a price-to-book ratio of 12.14 reflecting a rich premium to book value. The P/FCF stands at -33.49, also below market averages. Compared to sector medians, Ardelyx, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.
Dividend & Fair Value
Ardelyx, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.60. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Ardelyx, Inc. generated EPS of -$0.24 over the past year. Five-year average earnings growth is 35.34%. The latest quarter delivered EPS of -$0.00. The next quarter is forecast at $0.02. Next year's EPS is expected at $19.60. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 6 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $17.00 to $5.50. The high target offers 119.64% upside. The low target suggests -28.94% downside. The mean target is $11.31. This offers 46.12% upside. Ardelyx, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by -93.32%. The prior quarter beat by -38.46%. Over the last six quarters, Apple has recorded several small beats. These include -30.0% in August 01, 2024.
Shareholding & Insider Activity
Ardelyx, Inc. has 242.97 million shares outstanding. The public float is 234.60 million shares, elevated short interest at 9.62% of float. This equals 20.66 million shares. The short ratio is 7.54 days. Institutional investors hold 69.26% of the float. Insiders own 2.75%. MOTT DAVID M holds 2.90 million shares, RAAB MICHAEL has 1.46 million shares and Rodriguez Susan has 449.09 thousand shares. Over the past six months, insider transactions show net selling. They sold 197.32 thousand shares across 13 transactions.
Financial & Profitability Overview
On valuation metrics, Ardelyx trades at a P/E of -33.11, P/S of 4.65 and P/B of 12.14. The current ratio is 4.41 and quick ratio is 4.11. Operationally, the company’s inventory turnover is 1.67 and cash conversion cycle is 129.23 days. Debt-to-equity is 1.35, supported by a cash flow-to-debt ratio of -0.26.
Quarterly Financial Highlights
The company ended the quarter with $184.30M in cash and short-term investments, a total debt of $55.98M, and net debt of $34.51M. Total assets were $297.58M, with equity of $166.82M. Financials further reflected weakness, with operating cash flow of - $89.72M, free cash flow of - $90.06M, and capital expenditures of - $344.00K.
Frequently Asked Questions
What is the current Ardelyx, Inc. (ARDX) stock price?
Ardelyx, Inc. (NASDAQ: ARDX) stock price is $7.74 in the last trading session. During the trading session, ARDX stock reached the peak price of $8.05 while $7.22 was the lowest point it dropped to. The percentage change in ARDX stock occurred in the recent session was 10.57% while the dollar amount for the price change in ARDX stock was $0.74.
ARDX's industry and sector of operation?
The NASDAQ listed ARDX is part of Biotechnology industry that operates in the broader Healthcare sector. Ardelyx, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ARDX?
Dan Pavicich
Senior Director of Market Devel.
Ms. Susan Rodriguez
Chief Commercial Officer
Mr. Robert Felsch
Senior Vice President of Fin. & Chief Accounting Officer
Ms. Elizabeth A. Grammer
Chief Legal & Admin. Officer and Sec.
Ms. Kimia Keshtbod
Mang. of Corporation Communications & Investor Relations
Mr. Michael G. Raab
Pres, Chief Executive Officer & Director
Mr. Justin A. Renz CPA, M.S.T., MBA, MST
Chief Financial & Operations Officer and Treasurer
Dr. Laura A. Williams M.D., M.P.H.
Chief Medical Officer
Mr. David P. Rosenbaum
Chief Devel. Officer
Mr. Robert C. Blanks
Chief Regulatory Affairs & Quality Assurance Officer
Ms. Karen Harrigan
Senior Director Market Devel.
Ms. Charon Spencer Sr.
Chief HR Officer
Ms. Elizabeth A. Grammer Esq.
Chief Legal & Admin. Officer and Sec.
Ms. Caitlin Lowie
Vice President of Communications & IR
Senior Director of Market Devel.
Ms. Susan Rodriguez
Chief Commercial Officer
Mr. Robert Felsch
Senior Vice President of Fin. & Chief Accounting Officer
Ms. Elizabeth A. Grammer
Chief Legal & Admin. Officer and Sec.
Ms. Kimia Keshtbod
Mang. of Corporation Communications & Investor Relations
Mr. Michael G. Raab
Pres, Chief Executive Officer & Director
Mr. Justin A. Renz CPA, M.S.T., MBA, MST
Chief Financial & Operations Officer and Treasurer
Dr. Laura A. Williams M.D., M.P.H.
Chief Medical Officer
Mr. David P. Rosenbaum
Chief Devel. Officer
Mr. Robert C. Blanks
Chief Regulatory Affairs & Quality Assurance Officer
Ms. Karen Harrigan
Senior Director Market Devel.
Ms. Charon Spencer Sr.
Chief HR Officer
Ms. Elizabeth A. Grammer Esq.
Chief Legal & Admin. Officer and Sec.
Ms. Caitlin Lowie
Vice President of Communications & IR
How ARDX did perform over past 52-week?
ARDX's closing price is 141.12% higher than its 52-week low of $3.21 where as its distance from 52-week high of $8.05 is -3.85%.
How many employees does ARDX have?
Number of ARDX employees currently stands at 395.
Link for ARDX official website?
Official Website of ARDX is: https://www.ardelyx.com
How do I contact ARDX?
ARDX could be contacted at phone 510 745 1700 and can also be accessed through its website. ARDX operates from 400 Fifth Avenue, Waltham, MA 02451, United States.
How many shares of ARDX are traded daily?
ARDX stock volume for the day was 17.85M shares. The average number of ARDX shares traded daily for last 3 months was 4.04M.
What is the market cap of ARDX currently?
The market value of ARDX currently stands at $1.85B with its latest stock price at $7.74 and 239.47M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep